Jeena Sikho Lifecare Limited has informed the Exchange about Transcript
JSLL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jeena Sikho Lifecare reported a strong Q3 FY26 with operating revenue of ₹221.7 crores (up 92% YoY, 17% QoQ), EBITDA of ₹100.8 crores (up 240% YoY) at a 45% margin, and profit after tax of ₹66.7 crores (up ~400% YoY) at a 30% margin, with EPS of ₹5.37. Management reiterated a multi-year roadmap targeting 7,000–10,000 operational beds in 3–5 years (versus 2,290 currently), 16 product launches in 2026, and a long-term profit target of ₹1,000 crores from a projected FY26 base of ~₹225 crores. The company has signed an exclusive Ayurveda distribution deal with Entero, giving access to 1.25 lakh medical stores, and is expanding internationally (UAE, Nepal, Kazakhstan, with US being evaluated). Management confirmed it is actively evaluating a 'high-level acquisition or tie-up' that could 'double or triple' the growth trajectory, while reducing government business exposure in favor of health insurance where day-care reimbursements have begun.
Triple-digit profit growth, strong 45% EBITDA margin, and clear long-term targets should reinforce positive sentiment, though expectations are already high. Disclosure of acquisition plans and the Entero tie-up are incremental positives for revenue visibility, while international expansion adds optionality on long-term growth.